O-Methylguanine has been measured in peripheral blood leukocytes of 14 patients during one or more cycles of treatment with procarbazine (daily treatment for 10 days) and in 12 patients during one or more cydes of treatment with dacarbazine (single dose per cycle). Adduct fornation at levels up to about 04 fmole/Ag DNA was detected in all procarbazineand all but one dacarbazine-treated patients at some point after treatment. O-Methylguanine accumulated during procarbazine treatment in a dose-related manner (mean rate of accumulation 2.8 x 10-4 fmole4pg DNA per mg/ni2 dose) and appeared to approach a plateau by the end of the cycle (above 600 mg/m2 cumulative dose). The average rate of O-methylguanine formation 2 hr after dacarbazine treatment was 11 ± 8 x 10-4 fmole/pg DNA per mg/m2 dose. Individuals examined on more than one treatment cycle with either drug showed broadly similar methylation responses. The rate of adduct accumulation showed a nonsignificant, negative correlation with the pretreatment lymphocyte levels of the repair enzyme O-alkylguanine-DNA alkyltransferase (AGI) in the case of procarbazine and no correlation in the case of dacarbazine. No consistent lymphocyte AGT depletion was noted as a result of treatment with either drug.
Introduction
The measurement of DNA adducts formed in patients treated with alkylating drugs is of interest because such adducts may indicate the biological dose received at the level of the individual patient, which may be correlated with therapeutic response or long-term complications (mainly therapy-induced carcino-genesis). During the past 2 years we have focused our attention on two methylating agents used in the chemotherapy of Hodgkin's lymphoma, procarbazine (PCZ) [N-isopropyl-a-(2-methylhydrazino)-p-toluamide] and dacarbazine (DCZ) [5-(3,3- dimethyl-1-triazeno)imidazole-4-carboxamide] (1,2). Both drugs are converted by metabolism to SN 1-type methylating intermediates and give rise to a range of DNA adducts, including 06-methylguanine (06-MeG) (3, 4) , an adduct believed to play an important role in carcinogenesis, mutagenesis, and cytotoxicity (5) (6) (7) . One of the most widely used therapeutic protocols for Hodgkin's lymphoma, the MOPP protocol (using PCZ in combination with nitrogen mustard, vincristine, and prednisone), has been shown to be associated with an increased risk ofacute nonlymphocytic leukemia in treated individuals, giving rise to a cumulative risk of more than 10% KYRTOPOULOS ETAL. within 10 years oftreatment (8) (9) (10) ). An alternative protocol, the ABVD protocol (using dacarbazine in combination with adriamycin, bleomycin, and vincristine), although not so far shown to be leukemogenic, may not be completely free ofcarcinogenic risk (11) .
Apart from considerations of therapy-induced carcinogenesis, an additional reason that makes the study of the methylation of human DNA by PCZ and DCZ of interest is the need to develop methodologies for assessing of the risks posed to the general population by exposure to environmental methylating agents. Such exposure is known to occur widely via contact with exogenous or endogenously formed chemicals (12-15). Here we review the current status of our ongoing studies and discuss the observed relationships between exposure dose, adduct formation, DNA repair and biological effects and discuss their usefulness in the assessment ofcancer risk associated with exposure to PCZ and DCZ and to environmental methylating agents.
Materials and Methods
Procarbazine treatment of patients involved 50-mg doses, three times per day (about 80 mg/m2day) for 10 consecutive days, followed by a 3-week rest period, a treatment normally 
Results and Discussion
Fourteen patients (twelve with Hodgkin's lymphoma and two with non-Hodgkin's lymphoma) on PCZ treatment and twelve In all cases where data were available for the 24 hr immediately after cessation of treatment, a decrease in adduct levels was observed amounting to 44 8 % (n = 3) for PCZ-treated individuals and 43 ± 19 % (n = 7) for DCZ-treated individuals.
As indicated in Figure 3 , the accumulation of 06-MeG in PCZtreated individuals as a group is linearly related to cumulative dose (with a slope of 2.8 x 10 4 fmole/jLg DNA per mg/M2 dose) and approaches a plateau above a cumulative dose of 600 mg/i2. In DCZ-treated individuals, the average level of 06-MeG found 2 hr after exposure was 0.20 ± 0.14 fmole/pg DNA, corresponding to a rate of formation of 11 ± 8 x i0 4 fmole/Ag DNA per mg/m2 dose.
As already reported, no consistent changes in lymphocyte AGT levels were observed during PCZ treatment (1) and the average value ofAGT remained constant throughout the cycle. A similar picture was obtained with patients on DCZ treatment, where a) no significant differences were seen between AGT values before and after treatment and b) AGT levels in the same patients prior to the start of repeated cycles were sometimes constant and sometimes changed in either direction (2) . The overall picture that emerges from our studies is that no significant AGT depletion occurred in most cases as a result of suicide repair of 06-MeG adducts formed in the context ofthe chemotherapy protocols we examined. This can be explained by the large excess of lymphocyte AGT present in most individuals examined (usually 5-15 fmole4cg DNA) relative to the observed adduct levels and by the de novo synthesis of AGT (17) . Significant depletion in lymphocyte AGT was recently reported by Lee et al. (17) in melanoma patients treated with high doses of DCZ (up to 800 mg/m2), about 5-fold higher than the doses used in our protocols. Examination of 06-MeG accumulation in different individuals has provided evidence that interindividual variability of AGT levels may be an important parameter influencing adduct accumulation during exposure to PCZ (1) . Based on the currently available data, while an inverse trend between lymphocyte AGT and 06-MeG accumulation is consistently observed, this correlation does not reach statistical significance (Fig. 4) Figure  I A-G. Samples collected after day 10 were excluded, as were samples collected after day 7 from individual no. 2 (for whom extensive loss ofmethylation was observed after day 7 Figure 7 describes a first approach toward using the above data to extrapolate the expected extent of 06-MeG formation in human blood leukocytes after exposure to DMN. Based on the comparison of 06-MeG formation in rat and human blood leukocytes by PCZ and assuming similar relative species susceptibilities to DMN-induced methylation, current daily human exposure to DMN (0.1-10 tsg) (12, 19) would be expected to give rise to 06-MeG levels well below 1 x 10 9 mole/mole guanine. 
